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Edited by Richard MaraisAbstract This study demonstrates a requirement for NF-jB
activation in cis-diamminedichloroplatinum (cisplatin)-induced
apoptosis in human head and neck squamous cell carcinoma
(HNSCC) cell lines. This conclusion was supported by the fol-
lowing observations: cisplatin induced IjBa degradation and
NF-jB-dependent transcriptional activation prior to cell death;
pyrrolidine dithiocarbamate (PDTC), a chemical inhibitor of
NF-jB activation, prevented apoptosis; lactacystin, an inhibitor
of IjBa degradation, also prevented apoptosis; and ﬁnally, the
expression of a super-repressor mutant IjBa blocked apoptosis.
The expression of tumor necrosis factor a (TNFa) was promoted
by cisplatin treatment and was suppressed by PDTC treatment.
In addition, a neutralizing antibody against TNFa protected cells
from cisplatin-induced apoptosis. These ﬁndings suggest that
NF-jB activation is required for cisplatin-induced apoptosis
and TNFa may play an important role in NF-jB-mediated apop-
tosis in cisplatin-treated HNSCC cell lines.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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cis-Diamminedichloroplatinum (cisplatin) is a DNA-damag-
ing agent which has been used therapeutically in head and neck
cancer, both alone and in combination with other chemother-
apeutic agents or radiation therapy [1,2]. Apoptosis induced by
cisplatin is generally considered to be the result of its ability to
damage DNA [3], but the mechanisms by which the DNA
damage triggers apoptosis remain unclear. There is evidence
that cisplatin induces the activation of NF-jB and that this
NF-jB activity results in an increase in cisplatin resistance
[4]. Consistent with this, many studies have supported the gen-Abbreviations: Cisplatin, cis-diamminedichloroplatinum; PDTC,
pyrrolidine dithiocarbamate; HNSCC, head and neck squamous cell
carcinoma; TUNEL, TdT-mediated dUTP nick end labeling
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doi:10.1016/j.febslet.2005.12.012eral view that NF-jB activation delivers a survival signal that
protects cells from apoptosis [5,6] by promoting the expression
of survival factors, such as certain members of the inhibitor of
apoptosis (IAP) family (c-IAP1, c-IAP2, and XIAP) [7] and
the Bcl-2 homologues Bﬂ-1/A1 [8] and Bcl-xL [9].
In contrast, there are also many reports about a pro-apopto-
tic role for NF-jB. First, many potent NF-jB stimulators such
as TNF [10], ceramide [11], H2O2, and serum deprivation
[12,13] ultimately induce apoptosis. Second, both apoptosis
and the activation of NF-jB are suppressed by the NF-jB
inhibitor pyrrolidine dithiocarbamate (PDTC) [14]. Third,
the NF-jB-induced death receptor 4 (DR4), DR5 [15], TNF-
related apoptosis-inducing ligand (TRAIL) [16,17], Fas [18],
and Fas ligand (FasL) [19] all may promote cell death
[19,20]. Fourth, the upstream promoter regions of several
death genes contain potential NF-jB binding motifs [13].
These accumulated experimental data strongly suggest that
exogenous signals such as toxins or reactive oxygen species
activate NF-jB. This activation results in the transcription
of genes that later execute the apoptosis program [12,21,22].
These conﬂicting studies of the role of NF-jB in apoptosis
suggest that the eﬀects of many signaling molecules are depen-
dent upon cell content and/or stress. Genotoxic drugs aﬀect
many signal transduction pathways, and the ﬁnal outcome, cell
survival or death, may be determined by complicated interac-
tions between these signal transduction pathways.
This study examined the role of NF-jB activation in regulat-
ing cisplatin-induced apoptosis in human head and neck squa-
mous cell carcinoma (HNSCC) cell lines, and the results from
this study indicate that NF-jB activation is required for cis-
platin-induced apoptosis. In addition, experiments described
here demonstrate that TNFa, induced by NF-jB activity in
the cisplatin-treated HNSCC cell lines, may play important
roles in NF-jB-mediated apoptosis.2. Materials and methods
2.1. Cell culture
The human HNSCC cell lines HN3 and HN4 were derived from
patients with HNSCC [23] and were maintained in Dulbeccos
modiﬁed Eagles medium supplemented with 10% fetal bovine serum
(Gibco-BRL), 100 U of penicillin, and 100 lg of streptomycin/ml. Cellsblished by Elsevier B.V. All rights reserved.
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For the induction of apoptosis, cells were plated in 60-mm dishes
1 day prior to cisplatin treatment.
2.2. TUNEL staining
TdT-mediated dUTP nick end labeling (TUNEL) staining was
conducted using an in situ cell death detection kit, TMR Red, accord-
ing to the protocol supplied by the manufacturer (Roche Molecular
Biochemicals). Brieﬂy, cells were plated in 60-mm dishes at 2 · 105
cells/ml DMEM. On the following day, the cells were treated with cis-
platin, harvested, and ﬁxed with 2% paraformaldehyde solution and
permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate. After
washing twice with PBS (137 mM NaCl; 2.7 mM KCl; 4.3 mM Na2H-
PO4 Æ 7H2O; and 1.4 mM KH2PO4; pH 7.2), cells were incubated in a
TUNEL reaction mixture containing terminal deoxynucleotidyl trans-
ferase and tetramethyl-rhodamine-dUTP. Cells were analyzed for ﬂuo-
rescence intensity using a FACS ﬂow cytometer (Becton–Dickinson
Inc.) and FluoView 500 confocal microscope (Olympus).
The eﬀect of the caspase-8 inhibitor, z-IETD-fmk (Calbiochem,
USA), on cisplatin-induced apoptosis was determined by adding 10 or
30 lM z-IETD-fmk to cells 1 h prior to treatment with 40 lM cisplatin.
2.3. Annexin V staining
Annexin V staining was conducted using an Annexin-V-FLUOS
staining kit, according to the protocol supplied by the manufacturer
(Roche Molecular Biochemicals). Brieﬂy, cells were washed twice with
PBS and resuspended in a binding buﬀer (0.01 M HEPES, pH 7.4;
0.14 M NaCl; and 2.5 mM CaCl2) containing Annexin V. Cells were
analyzed for ﬂuorescence intensity using a FACS ﬂow cytometer (Bec-
ton–Dickinson).
2.4. Caspase-8 activity assay
Caspase-8 activity was assayed using a Caspase-8 Colorimetric As-
say Kit (BD ApoAlert Caspase Colorimetric Assay Kit), according
to the protocol supplied by the manufacturer (BD Biosciences). Brieﬂy,
cells (2 · 106) were lysed in 50 ll lysis buﬀer for 10 min on ice. After
centrifugation in a microcentrifuge at maximum speed for 10 min at
4 C, supernatants were incubated with 5 ll of 4 mM caspase-8 sub-
strate, IETD-pNa, for 1 h at 37 C. Caspase-8 activity was determined
by reading absorbance at 405 nm taken against a blank containing buf-
fer and peptide alone.
2.5. Propidium iodide staining
Cells were plated in 60-mm dishes at 2 · 105 cells/ml DMEM. On the
following day, the cells were treated with cisplatin for 6 h, ﬁxed with
2% paraformaldehyde solution, and incubated with propidium iodide
buﬀer (0.1% sodium citrate, 0.1% Triton X-100, and 0.1 mg/ml propi-
dium iodide). Subsequently, nuclei of the cells were observed with a
FluoView 500 confocal microscope (Olymphus).
2.6. Immunoblot analysis
Cells were washed twice with cold PBS, and 30–50 lg of protein was
resolved by SDS–PAGE, transferred onto Hybond-P membranes
(Amersham Biosciences Inc.), and probed with appropriate dilutions
of the following primary antibodies: anti-IjBa (C-21) (Santa Cruz Bio-
technology Inc.) and anti-caspase 8 (Ab3) (Oncogene Research Prod-
uct). Immunoreactivity was detected using the ECL detection system
(Amersham Biosciences). The ﬁlms were exposed at multiple time
points to ensure that the images were not saturated.
2.7. Exposure to TNFa or an anti-TNFa antibody
Cells were incubated in 10 or 50 ng/ml of TNFa (BD Biosciences
Pharmingen) for 24 h at 37 C or in 10, 50 or 100 lg/ml of anti-TNFa
antibody (Was) (BD Biosciences Pharmingen).
2.8. Exposure to NF-jB inhibitor or an inhibitor of IjB degradation
NF-jB activation was inhibited by incubating cells in 120 lMPDTC
(Sigma) or 10 lM lactacystin (Calbiochem, USA).
2.9. Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared as described [24]. Double-stranded
oligonucleotides containing a consensus binding site for c-Rel
(5 0-AGTTGAGGGGACTTTCCCAGGC-3 0) (Santa Cruz Biotechnol-ogy) were 5 0-end-labeled using polynucleotide kinase and [c-32P]dATP.
Nuclear extracts (2.5–5 lg) were incubated with 1 ll of labeled
oligonucleotide (20000 cpm) in 20 ll of incubation buﬀer (10 mM
Tris–HCl, 40 mM NaCl, 1 mM EDTA, 1 mM b-mercaptoethanol,
2% glycerol, and 1–2 lg of poly(dI–dC)) for 20 min at 25 C. The spec-
iﬁcity of NF-jB DNA-binding activity was conﬁrmed by competition
with mutant oligonucleotide. DNA–protein complexes were resolved
by electrophoresis in 5% non-denaturing polyacrylamide gels and ana-
lyzed by autoradiography. For supershift experiments, nuclear extracts
were incubated with 2 lg of anti-NF-jB p50 (E-10) (Santa Cruz
Biotechnology) for 1 h on ice before the labeled probe was added.
2.10. Transfection
HN4 cells expressing the IjBa mutant aSR were established by
transfection of 10 lg of pRcCMVIjBSR (Invitrogen) using Lipofect-
amine (Gibco-BRL), followed by selection with G418 (100 lg of
G418/ml; Gibco-BRL). A control cell line, HN4/pRcCMV, was gener-
ated by transfection with pRcCMV vector.
2.11. Real-time PCR
Five micrograms of DNase I-treated total RNA was reverse tran-
scribed using random priming and Superscript II reverse transcriptase
(Invitrogen) according to the manufacturers instructions. Quantitative
PCR was performed by monitoring in real time the increase in ﬂuores-
cence of the SYBR Green dye (Molecular Probes, Eugene, OR) on a
DNA Engine Opticon Continuous Fluorescence Detection System
(MJ Research Inc.) according to the manufacturers instructions. Spec-
iﬁcities of each primer pair were conﬁrmed by melting curve analysis
and agarose-gel electrophoresis. Primers were designed using the
Primer3 software: http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi. PCR primer pairs were as follows: Fas: AGGA-
CATGGCTTAGAAGTGG, CACCCCAAGTTAGATCTGGA;
FasL: GGATGTTTCAGCTCTTCCAC, CATAGGTGTCTTCCC-
ATTCC; TNFR1: GCTTCAGAAAACCACCTCAG, CACAC-
GGTGTTCTGTTTCTC; TNFa: CTGTAGCCCATGTTGTAGCA,
AGGTTGACCTTGGTCTGGTA; DR4: TGGAGTGACATC-
GAGTGTGT, GTTGTGAGCATTGTCCTCAG; DR5: AGCACT-
CACTGGAATGACCT, CACTCCAGGGTGTACAATCA; TRAIL:
GCTGATCGTGATCTTCACAG, GGTTTCCTCAGAGGTTCT-
CA; TNFR-associated factor 2 (TRAF2): CTACAAGATGTG-
TCTGCGTAT, CTCTGAAAAGAGGATGAAGTC; Fas-associated
death domain protein (FADD): CTCTCTGAGACTGCTAAG-
TAGG, AATAGGATTACCTTAGGAATAAGA.3. Results
3.1. Cisplatin treatment induces apoptosis in HN4 cells
Cisplatin treatment results in apoptosis in many diﬀerent cell
types. To examine the ability of cisplatin to induce apoptosis in
HN4 cells, cultures were treated with varying amounts of cis-
platin for 12 h, after which they were stained with TUNEL
and examined by FACS analysis. Cisplatin caused apoptosis
of HN4 cells in a dose-dependent manner, with a concentra-
tion of 40 lM cisplatin resulting in death of greater than
62% of the cell population by 12 h of treatment (Fig. 1A).
The kinetics of cisplatin-induced apoptosis was examined
using a 40 lM dose. Cisplatin-induced apoptosis was detect-
able after 5 h of treatment of cisplatin at this dose and in-
creased dramatically thereafter (Fig. 1B).
3.2. Cisplatin induces IjBa degradation and NF-jB activation
To determine whether or not cisplatin treatment enhances
NF-jB activity, ﬁrst the IjBa levels after treatment of HN4
cells with 40 lM cisplatin were determined. IjBa levels are
of importance in the regulation of NF-jB activity under most
conditions [25]. There was no signiﬁcant change in the IjBa le-
vel in untreated HN4 cells over time. However, a marked deg-
radation of IjBa was observed at 4 h after cisplatin treatment,
Fig. 1. Cisplatin treatment induces apoptosis of HN4 cells in a dose- and time-dependent manner. HN4 cells were treated either with diﬀerent doses
of cisplatin for 12 h (A) or 40 lM cisplatin for the indicated times (B). Cells were then ﬁxed with 2% paraformaldehyde, stained with TUNEL, and
analyzed by FACS. Cells analyzed under marker M1 are apoptotic (TUNEL positive). Data represent means ± S.D. of three independent
experiments.
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(Fig. 2A, left panel). After the initial degradation, the level
of IjBa gradually recovered with time, which was consistently
observed in three separate experiments.
An EMSA was performed with a speciﬁc NF-jB binding site
probe using a nuclear extract collected 4 h after cisplatin treat-
ment. Cisplatin-induced activation of NF-jB was demon-
strated by the increased levels of DNA–protein complexes in
cisplatin-treated HN4 cells compared to untreated HN4 cells
(Fig. 2B). The DNA–protein complexes were dramatically re-
duced by treatment with PDTC or preincubation of the reac-Fig. 2. Cisplatin treatment causes an increase in the DNA binding of NF-jB
cells were treated with control medium (no treatment) or 40 lM cisplatin. Cel
cell lysates (30 lg) were resolved by SDS–PAGE and immunoblotted to detec
and 4 h after cisplatin treatment, respectively, and were incubated with an NF
in cisplatin-treated HN3 and HN4 cells 6 and 4 h after cisplatin treatment, r
treatment or preincubation of the reaction mixture with an antibody to NF-tion mixture with an NF-jB p50-speciﬁc antibody (Fig. 2C),
which suggests that the protein in the DNA–protein complex
is NF-jB. Taken together, these results indicate that cisplatin
treatment increases the NF-jB activity in HN4 cells.
3.3. Cisplatin-induced apoptosis is blocked by PDTC, an NF-jB
inhibitor
To determine the role of NF-jB in the cisplatin-induced
apoptosis in HN4 cells, NF-jB activation was blocked by
pretreating cells with the NF-jB inhibitor PDTC for 30 min
prior to the addition of 40 lM cisplatin. PDTC treatment. (A) Cisplatin treatment increases IjBa degradation. HN3 and HN4
ls were collected at the indicated time after cisplatin treatment and total
t IjBa. (B) Nuclear extracts were collected from HN3 and HN4 cells 6
-jB DNA probe. DNA–protein complexes were signiﬁcantly increased
espectively. (C) The DNA–protein complexes were reduced by PDTC
jB p50.
314 S.B. Kim et al. / FEBS Letters 580 (2006) 311–318suppressed the NF-jB binding activity induced by cisplatin,
which conﬁrmed the inhibitory eﬀect of the PDTC on NF-
jB activity (Fig. 2C). Next, the eﬀect of PDTC on the cis-
platin-induced apoptosis in HN4 cells was examined. Cells
treated with cisplatin alone displayed typical features of apop-
tosis including condensation of nuclei (Fig. 3A). However, pre-
treatment of cells with PDTC markedly suppressed the
morphologic changes induced by cisplatin (Fig. 3A, top). To
conﬁrm the suppressive eﬀect of PDTC on cisplatin-induced
apoptosis in HN4 cells, cells treated with cisplatin in the pres-
ence or absence of PDTC were stained by TUNEL, and apop-
totic cells were observed with confocal microscopy. PDTC
reduced the cisplatin-induced apoptosis of HN4 cells from
60% to 4% (Fig. 3A, bottom and Fig. 3B). These results sug-
gest the possibility that, instead of a role in the protection of
cells against cisplatin-induced apoptosis, NF-jB activity,
upregulated by cisplatin treatment, may mediate cisplatin-in-
duced apoptosis.3.4. Cisplatin-induced apoptosis is blocked by proteasome and
IjB inhibitors
Activation of NF-jB requires the phosphorylation and ubiq-
uitin-mediated degradation of IjBa by the IKK complex. If
the activation of NF-jB is essential for cisplatin-induced apop-
tosis, the treatment of lactacystin, a speciﬁc proteasome inhib-
itor, may protect the HN4 cells from the cisplatin-induced
apoptosis by preventing the degradation of IjBa. The addition
of 10 lM lactacystin prevented cisplatin-induced IjBa degra-
dation in HN4 cells (Fig. 4A) and protected HN4 cells from
cisplatin-induced apoptosis (Fig. 4B). These results supportFig. 3. PDTC inhibits cisplatin-induced apoptosis. HN4 cells were treated w
40 lM cisplatin plus 120 lM PDTC for 6 h. Cells were stained with PI and
apoptotic cells are fragmented and condensed (A, top). Cells were ﬁxed with
confocal microscopy (A, bottom). (B) HN4 cells were collected 6 h after cispl
and were analyzed by FACS. The results are presented as the means ± S.D.the possibility that NF-jB activation mediates the cisplatin-in-
duced apoptosis.3.5. Expression of dominant negative mutant IjBaSR blocks
cisplatin-induced apoptosis
Although the above results demonstrated that inhibition of
NF-jB activity was associated with blocking of cisplatin-
induced apoptosis, they did not address whether NF-jB activ-
ity was directly involved in cisplatin-induced apoptosis in HN4
cells. Therefore, further experiments using a speciﬁc inhibitor
of NF-jB activity were performed. These experiments made
use of a mutant form of IjBa to block cisplatin-induced apop-
tosis in HN4 cells. To analyze the role of NF-jB activation by
cisplatin treatment, a stable transfectant derivative of HN4
was established. The HN4/IjBaSR cell line stably expresses
a non-degradable phosphorylation site mutant of IjBa (Ij-
BaSR) [26]. As a negative control, an HN4/pRcCMV cell line,
stably transfected with empty vector, was also created. We ver-
iﬁed the activity of the transfected protein by showing that cis-
platin-induced IjBa degradation was impaired in HN4/
IjBaSR cells (Fig. 5A). Induction of apoptosis in HN4/
pRcCMV and HN4/IjBaSR cells treated with cisplatin was
analyzed by TUNEL staining. HN4/pRcCMV cells were very
sensitive to cisplatin-induced apoptosis (Fig. 5B), with more
than 60% of cells showing apoptosis when treated with
40 lM cisplatin. In IjBaSR-expressing cells, however, there
was a pronounced decrease in the sensitivity to cisplatin, with
only 5% of cells showing apoptosis (Fig. 5B). These results
indicate that NF-jB activation is important in cisplatin-
induced apoptosis.ith control medium (no treatment), 40 lM cisplatin, 120 lM PDTC, or
the nuclei were examined using confocal microscopy. The nuclei of
2% paraformaldehyde, stained with TUNEL, and were observed with
atin treatment, ﬁxed with 2% paraformaldehyde, stained with TUNEL,
from three separate experiments.
Fig. 4. Lactacystin inhibits cisplatin-induced apoptosis. (A) Immuno-
blot analysis of IjBa degradation. HN4 cells were treated with 40 lM
cisplatin or 40 lM cisplatin plus 10 lM lactacystin. Cells were
harvested after cisplatin treatment for 4 h and analyzed for the
expression of IjBa by immunoblotting. (B) HN4 cells were treated
with control medium (no treatment), 40 lM cisplatin, 10 lM lactacy-
stin, or 40 lM cisplatin plus 10 lM lactacystin. Cells were then ﬁxed
with 2% paraformaldehyde, stained with TUNEL, and analyzed by
FACS. The results are presented as the means ± S.D. from three
separate experiments.
Fig. 5. IjBaSR inhibits cisplatin-induced apoptosis. (A) Immunoblot
analysis of IjBa degradation. The stable transfectant cell lines HN4,
HN4/IjBaSR, and HN4/pCMV were harvested after cisplatin treat-
ment for 4 h and analyzed for the expression of IjBa by immuno-
blotting. (B) IjBa expression in HN4/IjBaSR inhibited cisplatin-
induced apoptosis. Cells were treated with control medium (no
treatment) or 40 lM cisplatin. Cells were then ﬁxed with 2%
paraformaldehyde, stained with TUNEL, and analyzed by FACS.
The results are presented as the means ± S.D. from three separate
experiments.
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apoptosis in another cell line
Previous work has shown that both the HN3 and HN4 cell
lines are cisplatin sensitive [27]. To determine whether or not
NF-jB activation is also required for the cisplatin-induced
apoptosis in HN3 cells, we, ﬁrst, determined the change in
the IjBa level in cisplatin-treated HN3 cells over time. In three
separate experiments, a signiﬁcant decrease in the IjBa level
was observed at 6 h after cisplatin treatment and, after then,
the IjBa level gradually recovered at 8 h after cisplatin treat-
ment (Fig. 2A, right panel). The decrease in the IjBa level at
6 h after cisplatin treatment coincided with the increase in
the NF-jB activity determined by an EMSA using a nuclear
extract collected 6 h after cisplatin treatment in cisplatin-trea-
ted HN3 cells (Fig. 2C). Next, we treated HN3 cells with cis-
platin in the presence or absence of PDTC and lactacystin.
Apoptotic cells were stained by TUNEL and annexin V. Sim-
ilar to the HN4 cells, the addition of 10 lM lactacystin or
120 lM PDTC protected HN3 cells from cisplatin-induced
apoptosis (Fig. 6). These results suggest the possibility that
NF-jB activation mediates the cisplatin-induced apoptosis in
HN3 as well as in HN4 cells.
3.7. Caspase-8 activity is required for cisplatin-induced apoptosis
A reduction in the levels of caspase-8, a biochemical feature
of apoptosis, was detected within 6 h of cisplatin exposure by
Western blot analysis (Fig. 7A). To conﬁrm the ability of
cisplatin to activate caspase-8, caspase-8 activity was examined
in cell lysates from HN4 cells using in an in vitro chromogenicassay with IETD-pNa as a substrate. Cisplatin treatment in-
duced a 3.1-fold increase in caspase-8 activity in HN4 cells
(Fig. 7B). In addition, treatment with a caspase-8 inhibitor,
z-IETD-fmk, suppressed the caspase-8 activity (Fig. 7B) and
cisplatin-induced apoptosis (Fig. 7C) in HN4 cells. These re-
sults suggest that caspase-8 activity is required for the cis-
platin-induced apoptosis of HN4 cells.
3.8. TNFa is responsible for cisplatin-induced apoptosis
Caspase-8 is normally activated by the engagement of death
receptors which belong to the TNF receptor gene superfamily
[28]. Thus, it is possible that the NF-jB activity upregulated in
HN4 cells by cisplatin treatment may mediate apoptosis by
inducing TNF and the TNF receptor (TNFR) superfamily.
To determine whether members of this superfamily are in-
duced by cisplatin and are responsible for the cisplatin-induced
apoptosis in HN4 cells, the eﬀect of cisplatin treatment on their
expression levels was investigated. While cisplatin treatment
did not result in any signiﬁcant changes in the expression of
several genes, including CD95, DR4, DR5, TNFR1, FasL,
and TRAIL, the expression of TNFa was increased by 2.7-fold
by cisplatin treatment, and its expression was suppressed by
PDTC treatment (Table 1). These results strongly suggest that
TNFa is induced by NF-jB activity and may play a critical
role in cisplatin-induced apoptosis in HN4 cells.
To further examine the role of TNFa, levels of TNFa in the
supernatant of cisplatin-treated HN4 cells were assayed, but
no TNFa was detected (data not shown). It is possible that lev-
els of TNFa which are too low to be detectable are still enough
to induce the apoptosis. Thus, a neutralizing antibody against
TNFa was added to attempt to protect the cells. The TNFa
neutralizing antibody treatment resulted in a dose-dependent
reduction of the cisplatin-induced apoptosis of HN4 cells
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Fig. 6. PDTC and lactacystin inhibit cisplatin-induced apoptosis both in HN3 and HN4 cells. HN3 and HN4 cells were treated with control medium
(no treatment), 40 lM cisplatin, 120 lM PDTC, 10 lM lactacystin, 40 lM cisplatin plus 120 lM PDTC, or 40 lM cisplatin plus 10 lM lactacystin
for 6 h. Cells were then stained with TUNEL or annexin V, and were analyzed by FACS. The results are presented as the means ± S.D. from three
separate experiments.
Fig. 7. TNFa is responsible for cisplatin-induced apoptosis. (A) Cleavage of caspase-8 in HN4 cells treated with 40 lM cisplatin. Cells were
harvested at 6 h and cleavage was assessed by Western blot analysis using an anti-caspase-8 monoclonal antibody. (B) Caspase-8 activity was
measured in cells lysates at 6 h after cisplatin treatment. The caspase-8 activity of untreated HN4 cells was deﬁned as one. (C) Eﬀect of the caspase-8
inhibitor z-IETD-fmk on cisplatin-induced apoptosis in HN4 cells. HN4 cells were treated with 40 lM cisplatin in the absence or presence of z-
IETD-fmk (10 and 30 lM). Cisplatin-induced apoptosis was determined by TUNEL staining at 6 h after cisplatin treatment. Data represent
means ± S.D. of three independent experiments. (D) An anti-TNFa antibody protected HN4 cells from cisplatin-induced apoptosis. HN4 cells were
treated with the indicated concentration of cisplatin or anti-TNFa for 6 h or TNFa for 24 h. Cells were then collected, stained with TUNEL, and
were analyzed by ﬂow cytometry. The results are presented as the means ± S.D. from three separate experiments. (E) Semiquantitative RT-PCR
analysis. Total RNA samples were isolated from HN4 cells after cisplatin treatment for 4 and 6 h. Cisplatin treatment suppressed the expression of
TRAF2, as indicated by RT-PCR analysis.
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Table 1
Real-time PCR analysis of selected death receptor genes and their
ligands in the absence or presence of PDTC
Gene Fold change
Cisplatin Cisplatin + PDTC
Exp. 1 Exp. 2 Exp. 1 Exp. 2
CD95 (Fas) 0.86 0.92 0.38 0.25
TRAIL-R1 (DR4) 1.04 0.98 0.89 0.93
TRAIL-R2 (DR5) 0.65 0.72 0.67 0.59
TNFR1 0.38 0.51 0.41 0.49
CD95L (FasL) 1.02 1.05 0.43 0.52
TRAIL 0.29 0.24 0.11 0.14
TNFa 2.27 3.05 1.16 0.95
The fold-change values for real-time PCR were calculated by
the following equation: fold-change value =
2(Ct(CDDP- or CDDP + PDTC-treated HN4)  Ct(untreated HN4)).
S.B. Kim et al. / FEBS Letters 580 (2006) 311–318 317(Fig. 7D), and addition of 100 lg/ml anti-TNFa monoclonal
antibody reduced the cisplatin-induced apoptosis to 21%
(Fig. 7D). However, even though treatment with TNFa in
combination with cisplatin caused a slight increase in the cis-
platin-induced apoptosis, TNFa treatment alone did not in-
duce apoptosis in HN4 cells (Fig. 7D), which suggests that
TNFa is not enough to induce apoptosis in HN4 cells.
Binding of TNFa to its receptors can signal both cell sur-
vival and death by recruiting the intracellular proteins TRAF2
and FADD, respectively [29–31]. Thus, we determined whether
or not cisplatin treatment induced any changes in the expres-
sion levels of TRAF2 and FADD. While there was no signiﬁ-
cant change in the expression of FADD, the expression of
TRAF2 was signiﬁcantly reduced by cisplatin treatment in
HN4 cells (Fig. 7E). This change TRAF2 expression may be
required for TNFa to induce cell death in HN4 cells. Taken to-
gether, the results described above suggest that the cisplatin-in-
duced apoptosis may be mediated by NF-jB-induced TNFa.4. Discussion
The purpose of this study was to investigate the role of NF-
jB activity in the cisplatin-induced apoptosis of HNSCC cell
lines. In this report, we showed that the cisplatin treatment in-
duced IjBa degradation and NF-jB activation, prior to cell
death. In addition, the small-molecule NF-jB inhibitor PDTC
suppressed cisplatin-induced apoptosis, and a speciﬁc protea-
some inhibitor, lactacystin, prevented cell death. Finally, inhi-
bition of NF-jB activity by expression of mutant form of IjBa
signiﬁcantly reduced the cisplatin-induced apoptosis. Thus, cis-
platin-induced NF-jB activation is required for the cisplatin-
induced apoptosis in HNSCC cells.
This ﬁnding was unexpected because many studies have sup-
ported the general view that NF-jB activation delivers a
survival signal that protects cell from apoptosis [5,6]. Consis-
tent with a prosurvival function for NF-jB, NF-jB activation
induced by cisplatin was found to protect cells from cisplatin-
induced apoptosis [4]. In contrast, other recent studies have
found evidence that NF-jB is a mediator of cell death
[10–15]. NF-jB has been reported to mediate cell death by
inducing the expression of the TNFR superfamily, including
members such as CD95 (Fas) [18,32], TRAIL-R1 (DR4) [15],
and TRAIL-R2 (DR5) [15,33], or their respective cognatedeath ligands, such as TRAIL [16,33,34]. The death signal
from the surface death receptors recruits caspase 8, facilitating
the connection from death receptor to eﬀector caspases [28,35].
How NF-jB acts to kill HNSCC cells after cisplatin treat-
ment is unclear. As described above, it is possible that NF-
jB activates TNFR superfamily-mediated apoptosis. In HN4
cells, NF-jB, activated by cisplatin treatment, resulted in an
increase in the expression of TNFa, which has been reported
to be induced by NF-jB activity [36,37]. Binding of TNFa
to its receptors initiates a signaling pathway by recruiting
intracellular proteins which couple the receptors to intracellu-
lar signaling pathways. It is well known that the receptor-inter-
acting protein (RIP), TRAF2, and FADD are important
eﬀector molecules of TNFR1 signaling [29–31]. RIP and
TRAF2 mainly act as cell survival factors to protect against
TNF-induced apoptosis via NF-jB activation [29,38,39]. On
the other hand, FADD interacts with and activates caspase 8
to initiate the apoptotic cell death pathway [28,35]. In cis-
platin-treated HN4 cells, our results showed that TNFa
seemed to signal cell death. This was supported by the degra-
dation of pro-caspase-8 seen with cisplatin treatment, the sup-
pression of cisplatin-induced apoptosis by a caspase-8
inhibitor, and suppression of cisplatin-induced apoptosis by
the neutralization of TNFa. We did not investigate in detail
how TNFa contributes to cell death in cisplatin-treated HN4
cells. However, we observed a signiﬁcant decrease in the
expression of TRAF2, which has been reported to be a key
molecule for survival signaling from TNFa [29,38,39]. Thus,
it is possible that reduced expression levels of TRAF2 resulting
from cisplatin treatment can lead to the apoptotic cell death of
HN4 cells in response to TNFa.
TRAF2 has been reported to be an NF-jB target gene [40].
In our study, while the expression level of TNFa, another NF-
jB target gene, was increased by cisplatin treatment, TRAF2
expression was decreased. It is possible that jB sites in TNFa
and TRAF2 genes may exhibit diﬀerent preferences for partic-
ular subunits comprising the NF-jB dimer, and cisplatin treat-
ment may regulate the expression of these NF-jB target genes
by activation of particular subunits of the NF-jB dimer. It will
be important to determine which subunits of NF-jB are acti-
vated by cisplatin treatment and whether the activation of
these subunits is necessary for the expression of TNFa and
apoptosis in cisplatin-treated in HN4 cells.
Our study links cisplatin-induced apoptosis and the activa-
tion of NF-jB in HNSCC cells. Based upon our results, it is
possible that NF-jB, activated by cisplatin, induces the expres-
sion of TNFa, which may be involved in the cisplatin-induced
apoptosis. A better understanding of which subunits of NF-jB
are activated by cisplatin treatment and analysis of the target
genes of the particular subunits of NF-jB will enable us to de-
ﬁne the mechanism underlying the cisplatin-induced apoptosis
of HNSCC cells.
Acknowledgments: This project was supported by the Research fund
from the University of Ulsan. Jong Soo Kim was partly supported
by the BK21 program of the Korean Research Foundation.References
[1] Herskovic, A., Martz, K., al-Sarraf, M., Leichman, L., Brindle, J.,
Vaitkevicius, V., Cooper, J., Byhardt, R., Davis, L. and Emami,
B. (1992) Combined chemotherapy and radiotherapy compared
318 S.B. Kim et al. / FEBS Letters 580 (2006) 311–318with radiotherapy alone in patients with cancer of the esophagus.
N. Engl. J. Med. 326, 1593–1598.
[2] de Andres, L., Brunet, J., Lopez-Pousa, A., Burgues, J., Vega, M.,
Tabernero, J.M., Mesia, R. and Lopez, J. (1995) Randomized
trial of neoadjuvant cisplatin and ﬂuorouracil versus carboplatin
and ﬂuorouracil in patients with stage IV-M0 head and neck
cancer. J. Clin. Oncol. 13, 1493–1500.
[3] Eastman, A. (1990) Activation of programmed cell death by
anticancer agents: cisplatin as a model system. Cancer Cell 2, 275–
280.
[4] Rong, R., He, Q., Liu, Y., Sheikh, M.S. and Huang, Y. (2002)
TC21 mediates transformation and cell survival via activation of
phosphatidylinositol 3-kinase/Akt and NF-kappaB signaling
pathway. Oncogene 21, 1062–1070.
[5] Beg, A.A. and Baltimore, D. (1996) An essential role for NF-
kappaB in preventing TNF-alpha-induced cell death. Science 274,
782–784.
[6] Van Antwerp, D.J., Martin, S.J., Kafri, T., Green, D.R. and
Verma, I.M. (1996) Suppression of TNF-alpha-induced apoptosis
by NF-kappaB. Science 274, 787–789.
[7] Rayet, B. and Gelinas, C. (1999) Aberrant rel/nfkb genes and
activity in human cancer. Oncogene 18, 6938–6947.
[8] Wang, C.Y., Guttridge, D.C., Mayo, M.W. and Baldwin Jr., A.S.
(1999) NF-kappaB induces expression of the Bcl-2 homologue
A1/Bﬂ-1 to preferentially suppress chemotherapy-induced apop-
tosis. Mol. Cell. Biol. 19, 5923–5929.
[9] Visconti, R., Cerutti, J., Battista, S., Fedele, M., Trapasso, F.,
Zeki, K., Miano, M.P., de Nigris, F., Casalino, L., Curcio, F.,
Santoro, M. and Fusco, A. (1997) Expression of the neoplastic
phenotype by human thyroid carcinoma cell lines requires
NFkappaB p65 protein expression. Oncogene 15, 1987–1994.
[10] Barger, S.W., Horster, D., Furukawa, K., Goddman, Y., Krie-
glestein, J. and Mattson, M.P. (1995) Tumor necrosis factors
alpha and beta protect neurons against amyloid beta-peptide
toxicity: evidence for involvement of a kappa B-binding factor
and attenuation of peroxide and Ca2+ accumulation. Proc. Natl.
Acad. Sci. USA 92, 9328–9332.
[11] Hunot, S., Brugg, B., Ricard, D., Michel, P.P., Muriel, M.P.,
Ruberg, M., Faucheux, B.A., Agid, Y. and Hirsch, E.C. (1997)
Nuclear translocation of NF-kappaB is increased in dopaminergic
neurons of patients with parkinson disease. Proc. Natl. Acad. Sci.
USA 94, 7531–7536.
[12] Tong, L. and Perez-Polo, J.R. (1995) Transcription factor DNA
binding activity in PC12 cells undergoing apoptosis after glucose
deprivation. Neurosci. Lett. 191, 137–140.
[13] Grimm, S., Bauer, M.K., Baeuerle, P.A. and Schulze-Osthoﬀ, K.
(1996) Bcl-2 down-regulates the activity of transcription factor
NF-kappaB induced upon apoptosis. J. Cell Biol. 134, 13–23.
[14] Bian, X., McAllister-Lucas, L.M., Shao, F., Schumacher, K.R.,
Feng, Z., Porter, A.G., Castle, V.P. and Opipari, A.W. (2001)
NF-kappa B activation mediates doxorubicin-induced cell death
in N-type neuroblastoma cells. J. Biol. Chem. 276, 48921–48929.
[15] Ravi, R., Bedi, G.C., Engstrom, L.W., Zeng, Q., Mookerjee, B.,
Gelinas, C., Fuchs, E.J. and Bedi, A. (2001) Regulation of death
receptor expression and TRAIL/Apo2L-induced apoptosis by
NF-kappaB. Nat. Cell Biol. 3, 409–416.
[16] Rivera-Walsh, I., Waterﬁeld, M., Xiao, G., Fong, A. and Sun,
S.C. (2001) NF-kappaB signaling pathway governs TRAIL gene
expression and human T-cell leukemia virus-I Tax-induced T-cell
death. J. Biol. Chem. 276, 40385–40388.
[17] Baetu, T.M., Kwon, H., Sharma, S., Grandvaux, N. and Hiscott,
J. (2001) Disruption of NF-kappaB signaling reveals a novel role
for NF-kappaB in the regulation of TNF-related apoptosis-
inducing ligand expression. J. Immunol. 167, 3164–3173.
[18] Zheng, Y., Ouaaz, F., Bruzzo, P., Singh, V., Gerondakis, S. and
Beg, A.A. (2001) NF-kappa B RelA (p65) is essential for TNF-
alpha-induced fas expression but dispensable for both TCR-
induced expression and activation-induced cell death. J. Immunol.
166, 4949–4957.
[19] Lin, B., Williams-Skipp, C., Tao, Y., Schleicher, M.S., Cano,
L.L., Duke, R.C. and Scheinman, R. (1999) NF-kappaB func-
tions as both a proapoptotic and antiapoptotic regulatory factor
within a single cell type. Cell Death Diﬀer. 6, 570–582.[20] Ryan, K.M., Ernst, M.K., Rice, N.R. and Vousden, K.H. (2000)
Role of NF-kappaB in p53-mediated programmed cell death.
Nature 404, 892–897.
[21] Grilli, M., Pizzi, M., Memo, M. and Spano, P. (1996) Neuropro-
tection by aspirin and sodium salicylate through blockade of NF-
kappaB activation. Science 274, 1383–1385.
[22] Grilli, M. and Memo, M. (1999) Possible role of NF-kappaB and
p53 in the glutamate-induced pro-apoptotic neuronal pathway.
Cell Death Diﬀer. 6, 22–27.
[23] Kim, S.Y., Chu, K.C., Lee, H.R., Lee, K.S. and Carey, T.E.
(1997) Establishment and characterization of nine new head and
neck cancer cell lines. Acta Otolaryngol. 117, 775–784.
[24] Lee, H.W., Park, S.J., Choi, B.K., Kim, H.H., Nam, K.O. and
Kwon, B.S. (2002) 4-1BB promotes the survival of CD8+ T
lymphocytes by increasing expression of Bcl-xL and Bﬂ-1. J.
Immunol. 169, 4882–4888.
[25] Karin, M. and Ben-Neriah, Y. (2000) Phosphorylation meets
ubiquitination: the control of NF-[kappa]B activity. Annu. Rev.
Immunol. 18, 621–663.
[26] Brown, K., Gerstberger, S., Carlson, L., Franzoso, G. and
Siebenlist, U. (1995) Control of I kappa B-alpha proteolysis by
site-speciﬁc, signal-induced phosphorylation. Science 267, 1485–
1488.
[27] Lee, S.K., Kim, S.B., Kim, J.S., Moon, C.H., Han, M.S., Lee,
B.J., Chung, D.K., Min, Y.J., Park, J.H., Choi, D.H., Cho, H.R.,
Park, S.K. and Park, J.W. (2005) Butyrate response factor 1
enhances cisplatin sensitivity in human head and neck squamous
cell carcinoma cell lines. Int. J. Cancer 117, 32–40.
[28] Ashkenazi, A. and Dixit, V.M. (1998) Death receptors: signaling
and modulation. Science 281, 1305–1308.
[29] Baud, V. and Karin, M. (2001) Signal transduction by tumor
necrosis factor and its relatives. Trends Cell Biol. 11, 372–377.
[30] Chen, G. and Goeddel, D.V. (2002) TNF-R1 signaling: a
beautiful pathway. Science 296, 1634–1635.
[31] Mak, T.W. and Yeh, W.C. (2002) Signaling for survival and
apoptosis in the immune system. Arthritis Res. 4, S243–S252.
[32] Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mah-
boubi, A. and Green, D.R. (1998) DNA damaging agents induce
expression of Fas ligand and subsequent apoptosis in T lympho-
cytes via the activation of NF-kappa B and AP-1. Mol. Cell 1,
543–551.
[33] Spalding, A.C., Jotte, R.M., Scheinman, R.I., Geraci, M.W.,
Clarke, P., Tyler, K.L. and Johnson, G. (2002) TRAIL and
inhibitors of apoptosis are opposing determinants for NF-
kappaB-dependent, genotoxin-induced genotoxin-induced apop-
tosis of cancer cells. Oncogene 21, 260–271.
[34] Wurzer, W.J., Ehrhardt, C., Pleschka, S., Berberich-Siebelt, F.,
Wolﬀ, T., Walczak, H., Planz, O. and Ludwig, S. (2004) NF-
kappaB-dependent induction of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for
eﬃcient inﬂuenza virus propagation. J. Biol. Chem. 279, 30931–
30937.
[35] Nicholson, D.W. and Thornberry, N.A. (1997) Caspases: killer
proteases. Trends Biol. Sci. 8, 299–306.
[36] Shakhov, A.N., Collart, M.A., Vassalli, P., Nedospasov, S.A. and
Jongeneel, C.V. (1990) Kappa B-type enhancers are involved in
lipopolysaccharide-mediated transcriptional activation of the
tumor necrosis factor alpha gene in primary macrophages. J.
Exp. Med. 171, 35–47.
[37] Collart, M.A., Baeuerle, P.A. and Vassalli, P. (1990) Regulation
of tumor necrosis factor alpha transcription in macrophages:
involvement of four kappa B-like motifs and of constitutive and
inducible forms of NF-kappa B. Mol. Cell. Biol. 10, 1498–1506.
[38] Karin, M. and Lin, A. (2002) NF-kappaB at the crossroads of life
and death. Nat. Immunol. 3, 221–227.
[39] Liu, Z.G., Hsu, H., Goeddel, D.V. and Karin, M. (1996)
Dissection of TNF receptor 1 eﬀector functions: JNK activation
is not linked to apoptosis while NF-kappaB activation prevents
cell death. Cell 87, 565–576.
[40] Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V. and
Baldwin Jr., A.S. (1998) NF-kappaB antiapoptosis: induction of
TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-
8 activation. Science 281, 1680–1683.
